AC
MSLE

AXQ Capital’s Satellos Bioscience MSLE Stock Holding History

AXQ Capital’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,096
Closed -$56.8K – 1458
2026
Q1 		$56.8K Buy
+10,096
New +$99.2K 0.01% 921

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

AXQ Capital's MSLE Position: Q2 2026 in Review

AXQ Capital sold out of Satellos Bioscience (MSLE) in Q2 2026, closing a stake of 10,096 shares — an estimated $56.8K sold.

AXQ Capital first reported a position in MSLE in Q1 2026 and held it in 1 quarter. The position peaked at $56.8K in Q1 2026. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • AXQ Capital reported no remaining Satellos Bioscience position as of Q2 2026 after selling out during the quarter.
  • AXQ Capital sold 10,096 Satellos Bioscience shares in Q2 2026, an estimated $56.8K.
  • AXQ Capital first reported a position in Satellos Bioscience in Q1 2026 and held it in 1 quarter.
  • AXQ Capital's Satellos Bioscience position peaked at $56.8K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.